Allen (Biho) Seo 10/14/26 Allen (Biho) Seo 10/14/26

Orum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody Conjugate

Admin 8/23/26 Admin 8/23/26

Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate

Admin 4/18/26 Admin 4/18/26

Orum Presents New Preclinical Data at AACR 2026 on ORM-1153, a CD123-Targeting Degrader-Antibody Conjugate, Highlighting Broad Activity in AML and the Potential for Improved Efficacy and Tolerability

Admin 4/13/26 Admin 4/13/26

Orum Therapeutics Appoints Dr. Maria Koehler and Geoff Meyerson to Board of Directors

Kyuri Kim 3/18/26 Kyuri Kim 3/18/26

Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting 2026